Increased expression of SNHG16 usually predicted poor prognosis in multiple cancers including osteosarcoma [15], bladder cancer [16–18], esophagus cancer [19], non-small cell lung cancer (NSCLC) [11], glioma [20, 21], oral squamous cell carcinoma [13], hepatocellular carcinoma (HCC) [22], breast cancer [23], and ovarian cancer [24]. Here, SNHG16 is linked to ovarian carcinoma.